Project Grant R01AI192319
Award Date
6/9/25
Completion Date
5/31/30
Dollars Obligated
$798K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
This $2,345,463 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund a randomized, directly observed therapy (DOT) study to interpret clinical trials of doxycycline post-exposure prophylaxis (Doxy-PEP) for bacterial sexually transmitted infections (STIs). The study aims to develop in-depth adherence measurement techniques for doxycycline, establish dosing thresholds in hair,...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $911,400 Project Grant to Emory University to establish the PREMISE (PrEP Epidemiology, Modeling, and Surveillance) system. The goal is to use national PrEP prescription data, legal/policy coding, and natural experimental designs to inform the U.S. HIV epidemic response and understand which programs and policies are effective at facilitating...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $800,389.00 to Emory University to evaluate the safety and therapeutic potential of a novel HIV treatment strategy. The goal is to develop a combination therapy using soluble IL-15/IL-15RA-FC and TGF-beta pathway blockade, along with therapeutic vaccination, to enhance and restore anti-viral immunity and lead to sustained viral...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $617,376 to Emory University to conduct research on the activation and maturation of the HIV-1 virus. The key objectives are to: 1) Measure the timing of protease (PR) activation relative to HIV-1 budding from the host cell, 2) Assess the rate and extent of PR substrate cleavage and correlate this with formation of...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $195,896 to the University of Washington to conduct research on prevention strategies for Chlamydia trachomatis (CT) infections. The key objectives are to: 1) characterize the frequency and factors associated with antibiotic use among men who have sex with men in Seattle, to inform the potential utility of doxycycline prophylaxis; 2) develop...
This Project Grant award, totaling $2,127,639, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports a research project to develop a multi-level integrated strategy that combines two evidence-based interventions - "Many Men, Many Voices" (3MV) and "Client-Centered Care Coordination" (C4) - to optimize PrEP adherence and accelerate implementation at scale...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,155,836 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Miami. The funding will support a 5-year, randomized hybrid implementation/effectiveness trial titled "TEST-TO-PREP: A Randomized Hybrid Implementation/Efficacy Trial of a Social Network Strategy to Increase Equitable Reach of HIV Testing and PrEP Information." The study aims to evaluate the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Program (CFDA 93.855), provides $653,693 to Emory University to conduct research on the structural details of HIV-1 virion assembly, maturation, and entry. The work will leverage cryo-electron microscopy and tomography to interrogate the molecular determinants and cellular interactions involved in the HIV-1 capsid lattice formation and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $702,000 to support a 3-year project aimed at optimizing the implementation of long-acting injectable pre-exposure prophylaxis (LAI-PrEP) for HIV prevention. The key objectives are to: 1) Identify barriers and facilitators to LAI-PrEP implementation, 2) Determine optimal implementation strategies in partnership with...
This $1,272,341 cooperative agreement from the Centers for Disease Control and Prevention will support efforts to promote pre-exposure prophylaxis (PrEP) adherence among men who have sex with men of color. Awarded under the HIV Demonstration, Research, Public and Professional Education Projects program (CFDA 93.941), the University of North Carolina at Chapel Hill will work to develop and test improved HIV prevention strategies from September 2021 through October 2022. A subaward of $250,000...